By converting single-prediction design into a cross-validated, dynamics-tested workflow, UnibindMD provides a rapid, scalable, and generalizable path from any protein target to validated peptide-binder candidates.
Abstract
UnibindMD is an integrated computational platform that turns a protein target into validated de novo peptide-binder leads by chaining five orthogonal stages: deep-learning binder design (BindCraft), independent structure prediction and confidence assessment (AlphaFold3-class / Boltz-2), binding-affinity prediction (PRODIGY), developability profiling (ADMET-AI), and all-atom molecular-dynamics validation (GROMACS/CHARMM36m). The platform targets a persistent weakness of single-method design, namely that confidence metrics such as ipTM and pLDDT are self-consistent but not independent, so a design predicted to be confident may still be physically unstable. We demonstrate UnibindMD on three Andes virus (ANDV) intervention points, a setting of urgent need given a case fatality rate approaching 40%, a 2026 MV Hondius cruise-ship outbreak (13 cases, 3 deaths), and no approved therapeutic: the Gn-Gc glycoprotein complex (viral entry), the L-protein endonuclease domain (cap-snatching; PDB 6Q99), and the host VEGFR2 kinase (vascular permeability; PDB 2XIR). Across nine BindCraft campaigns (4,475 trajectories) the platform produced 464 accepted binders (acceptance 2.3–67.6%), with top candidates reaching ipTM = 0.94 and pLDDT = 0.94. The three selected leads were predicted by PRODIGY to bind with ΔG = −9.1 to −11.1 kcal mol−1 (Kd ≈ 8 nM–0.2 µM), and all three remained stably bound over 100 ns of unrestrained molecular dynamics (receptor Cα RMSD ≤ 2.6 Å, retained peptide fold, ≥99.5% of frames preserving more than half of the initial interface contacts, and 75–82% helical content). ADMET-AI flagged the expected poor oral bioavailability of large polar peptides and no PAINS alerts. By converting single-prediction design into a cross-validated, dynamics-tested workflow, UnibindMD provides a rapid, scalable, and generalizable path from any protein target to validated peptide-binder candidates.
Together, these capabilities establish AnewDDE as an integrated engine for addressing challenging therapeutic targets and translating molecular insights into experimentally validated candidates at scale.
Conventional aptamer discovery by systematic evolution of ligands by exponential enrichment (SELEX) is often constrained by limited library capacity, PCR bias, and multi-round screening. The recent convergence of artificial intelligence with aptamer development is driving a paradigm shift from empirical screening towar...
Bo-Ming Cui, X. Lian, Wei-Wei Song et al.· Biotechnology Advances· 0 citations
De novo protein-binder design with deep-learning pipelines such as BindCraft2 has been reported to deliver experimental success rates of 10-100% against well-structured targets. Here we report the opposite tail: two BindCraft2 (v1.0.3) cyclic-peptide campaigns targeting the shallow K81 lactylation epitope of human lact...
A transparent pre-screen can prioritise compounds ahead of structure-based calculation at a fraction of its cost, and the uncertainty and applicability-domain terms act as an abstention mechanism rather than an accuracy gain, and that abstention is not free.
HelixDTA is introduced, a deep learning framework featuring a parallel dual-branch architecture that independently learns representations from two distinct but complementary modalities: sequence context and complete target structures that demonstrates significant potential to empower precision drug design and accelerat...
Shang Lou, Xu-Hua Li, Yu-Jie Peng et al.· Journal of Chemical Informat...· 0 citations
The current peptide renaissance-driven by metagenomic and proteomic mining, molecular de-extinction, protein language models, and generative or evolutionary design-is producing millions of candidates, but useful machine learning depends on experimentally anchored, context-rich labels. The Database of Antimicrobial Acti...
M. Pirtskhalava, Evgenia Alimbarashvili, Maia Grigolava et al.· Nucleic Acids Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.